ABSTRACT:
Favipiravir is an anti-viral agent used for the treatment of a large number of RNA viruses including influenza and was considered for the treatment of COVID-19. A new stability indicating RP-HPLC has been developed for the estimation of Favipiravir and the method was validated. Hypersil BDS C18 column was used for the chromatographic study with a flow rate 1ml/min (Detection wavelength 230nm). The LOD and LOQ were found to be 0.2918µg/mL and 0.9207µg/mL respectively. Linearity was observed over the concentration 1-300µg/mL with linear regression equation, y = 28444x + 21853 (R2 = 09998) and the method is precise, accurate and robust. Stress degradation studies were performed and the method was found to be selective and specific.
Cite this article:
N S Yamani, Mukthinuthalapati Mathrusri Annapurna. Stability Indicating RP-HPLC Method for the estimation of Favipiravir in API and Pharmaceutical Dosage Forms (Tablets). Research Journal of Pharmacy and Technology 2022; 15(12):5700.6 doi: 10.52711/0974-360X.2022.00961
Cite(Electronic):
N S Yamani, Mukthinuthalapati Mathrusri Annapurna. Stability Indicating RP-HPLC Method for the estimation of Favipiravir in API and Pharmaceutical Dosage Forms (Tablets). Research Journal of Pharmacy and Technology 2022; 15(12):5700.6 doi: 10.52711/0974-360X.2022.00961 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-12-55
REFERENCES:
1. Ghasemnejad-Berenji M and Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug. Res (Stuttg) 2021; 71: 166-170.
2. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, Soliman S, Elbahnasawy M, Badawi R and Tageldin MA. Efficacy of Favipiravir in COVID-19 treatment: a multi-center randomized study. s. 2021;166: 949-954.
3. Mamdouh RR, Kamal AB, Naglaa SAN and Magy MA. A novel, rapid and simple UPLC-MS/MS method for quantification of Favipiravir in human plasma: Application to a bioequivalence study. Biomedical Chromatography. 2021; 35(7): e5098.
4. Abd Allah FI, Abdelhmaid A, Himida M, Mostafa Elkashlan A and El-Attar AMM. Fully validated UPLC-MS/MS method for quantifying Favipiravir in human plasma boosted lean six sigma: An application for a bioequivalence study. Biomedical Chromatography. 2022; 36(9): e5381.
5. Morsy MI, Nouman EG, Abdallah YM, Zainelabdeen MA, Darwish MM, Hassan AY, Gouda AS, Rezk MR, Abdel-Megied AM and Marzouk HM. A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers. J Pharm Biomed Anal. 2021; 199: 114057.
6. Eryavuz Onmaz D, Abusoglu S, Onmaz M, Yerlikaya FH and Unlu A. Development and validation of a sensitive, fast and simple LC-MS/MS method for the quantitation of Favipiravir in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1176: 122768.
7. Divya Kumar V, Rambabu G, Naresh K, Ravindra M and Naresh Kumar K. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC-MS method. Biomedical Chromatography. 2022; 36(6): e5363.
8. İbrahim Bulduk. HPLC-UV method for quantification of Favipiravir in pharmaceutical formulations. Acta Chromatographica. 2021; 33(3): 209-215.
9. ICH Validation of analytical procedures: Text and methodology Q2 (R1), International Conference on Harmonization, 2005.
10. ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization, 2003.